Category: schizophrenia
-
AbbVie tumbles after new schizophrenia drug fails two trials
•
(Bloomberg) — AbbVie Inc. shares fell. (ABBV) fell by the most in three years after two mid-stage trials of its schizophrenia drug failed to meet their primary target, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year. . Most read from Bloomberg AbbVie said Monday…
-
Teva schizophrenia drug Phase III results excite analysts
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) saw its share price rise by 12.8% yesterday, amid high trading volume, to its highest level in five years. The stock price of $15.74 gave it a market value of $17.8 billion, after the company reported first-quarter results with…